Summary

Generics in Asia-Pacific

Summary

Generics in Asia-Pacific industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value and volume 2019-24, and forecast to 2029). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Highlights

- A generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and branded generics are included in our market scope. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included. Market value is evaluated at ex-factory prices. Market volume refers to the proportion of the total ethical pharmaceutical market in a country or region that is made up of generic drugs. Thus, it is a measure of the market share held by generics, rather than a direct measure of the total market volume. Regional volumes are calculated as averages of countries that comprise the region where volume data exists.
- The Asia-Pacific generics market recorded revenues of $206.1 billion in 2024, representing a compound annual growth rate (CAGR) of 10.5% between 2019 and 2024.
- Market consumption volume increased with a CAGR of 1.4% between 2019 and 2024, reaching a total of 75.3% of total pharma volume in 2024.
- In 2024, the revenue of the Asia-Pacific generics market experienced an annual growth of 10.1%. The market’s growth is driven by the rising prevalence of chronic diseases such as diabetes, hypertension, and cardiovascular conditions, increasing the demand for affordable, long-term medications.

Scope

- Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the generics market in Asia-Pacific
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Asia-Pacific
- Leading company profiles reveal details of key generics market players’ global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the Asia-Pacific generics market with five year forecasts by both value and volume

Reasons to Buy

- What was the size of the Asia-Pacific generics market by value in 2024?
- What will be the size of the Asia-Pacific generics market in 2029?
- What factors are affecting the strength of competition in the Asia-Pacific generics market?
- How has the market performed over the last five years?
- Who are the top competitors in Asia-Pacific's generics market?

ページTOPに戻る

Table of Contents

Table of Contents
1.Executive Summary
1.1.Market value
1.2.Market value forecast
1.3.Market volume
1.4.Market volume forecast
1.5.Geography segmentation
1.6.Market rivalry
1.7.Competitive landscape
2.Market Overview
2.1.Market definition
2.2.Market analysis
3.Market Data
3.1.Market value
3.2.Market volume
4.Market Segmentation
4.1.Geography segmentation
5.Market Outlook
5.1.Market value forecast
5.2.Market volume forecast
6.Five Forces Analysis
6.1.Summary
6.2.Buyer power
6.3.Supplier power
6.4.New entrants
6.5.Threat of substitutes
6.6.Degree of rivalry
7.Competitive Landscape
7.1.Who are the leading players?
7.2.What are the strategies of the leading players?
7.3.What are the most recent market developments?
8.Company Profiles
8.1.Viatris Inc
8.2.Teva Pharmaceutical Industries Ltd
8.3.Sun Pharmaceutical Industries Ltd
8.4.Sandoz Group AG
9.Macroeconomic Indicators
9.1.Country data
10.Appendix
10.1.Methodology
10.2.Industry associations
10.3.Related MarketLine research
10.4.About MarketLine

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1: Asia-Pacific generics market value: $ million, 2019-24
Table 2: Asia-Pacific generics market volume: % of total pharma volume, 2019-24
Table 3: Asia-Pacific generics market geography segmentation: $ million, 2024
Table 4: Asia-Pacific generics market value forecast: $ million, 2024-29
Table 5: Asia-Pacific generics market volume forecast: % of total pharma volume, 2024-29
Table 6: Viatris Inc: Key Facts
Table 7: Viatris Inc: Annual Financial Ratios
Table 8: Viatris Inc: Key Employees
Table 9: Teva Pharmaceutical Industries Ltd: Key Facts
Table 10: Teva Pharmaceutical Industries Ltd: Annual Financial Ratios
Table 11: Teva Pharmaceutical Industries Ltd: Key Employees
Table 12: Sun Pharmaceutical Industries Ltd: Key Facts
Table 13: Sun Pharmaceutical Industries Ltd: Annual Financial Ratios
Table 14: Sun Pharmaceutical Industries Ltd: Key Employees
Table 15: Sandoz Group AG: Key Facts
Table 16: Sandoz Group AG: Annual Financial Ratios
Table 17: Sandoz Group AG: Key Employees
Table 18: Asia-Pacific Exchange Rate, 2019-24